Tom 15, Nr 2 (2018)
Terapia chorób układu krążenia
Opublikowany online: 2018-09-09
Wytyczne ESC 2017 dotyczące postępowania w STEMI. Co się zmieniło od 2012 roku?
DOI: 10.5603/chsin.v15i2.58021
Choroby Serca i Naczyń 2018;15(2):91-98.
Streszczenie
W 2017 roku Europejskie Towarzystwo Kardiologiczne (ESC) opublikowało wytyczne dotyczące postępowania w ostrym zawale serca z przetrwałym uniesieniem odcinka ST (STEMI). Od poprzednich wytycznych minęło 5 lat. W tym czasie pojawiło się wiele badań, których wyniki bezpośredni wpływają na codzienną praktykę lekarską. W artykule podsumowano najważniejsze zmiany w najnowszych zaleceniach ESC dotyczących postępowania w STEMI.
Słowa kluczowe: STEMIwytyczneES
Referencje
- Ibanez B, James S, Agewall S, et al. ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018; 39(2): 119–177.
- Thygesen K, Alpert J, Jaffe A, et al. Third universal definition of myocardial infarction. Global Heart. 2012; 7(4): 275–295.
- Jernberg T. Swedeheart annual raport 2015. Karolinska Universiti Hospital, Huddinge, Stockholm 2016.
- Regitz-Zagrosek V, Oertelt-Prigione S, Prescott E, et al. EUGenMed Cardiovascular Clinical Study Group. Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes. Eur Heart J. 2016; 37(1): 24–34.
- Valgimigli M, Gagnor A, Calabró P, et al. MATRIX Investigators. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. Lancet. 2015; 385(9986): 2465–2476.
- Karrowni W, Vyas A, Giacomino B, et al. Radial versus femoral access for primary percutaneous interventions in ST-segment elevation myocardial infarction patients: a meta-analysis of randomized controlled trials. JACC Cardiovasc Interv. 2013; 6(8): 814–823.
- Mehta RH, Starr AZ, Lopes RD, et al. APEX AMI Investigators. Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention. JAMA. 2009; 301(17): 1779–1789.
- Stub D, Smith K, Bernard S, et al. AVOID Investigators. Air versus oxygen in ST-segment-elevation myocardial infarction. Circulation. 2015; 131(24): 2143–2150.
- Farquhar H, Weatherall M, Wijesinghe M, et al. Systematic review of studies of the effect of hyperoxia on coronary blood flow. Am Heart J. 2009; 158(3): 371–377.
- Kenmure ACF, Murdoch WR, Beattie AD, et al. Circulatory and metabolic effects of oxygen in myocardial infarction. Br Med J. 1968; 4(5627): 360–364.
- Reinhart K, Bloos F, König F, et al. Reversible decrease of oxygen consumption by hyperoxia. Chest. 1991; 99(3): 690–694.
- Kawecki D, Gierlotka M, Morawiec B, et al. Direct admission versus interhospital transfer for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2017; 10(5): 438–447.
- Armstrong PW, Gershlick AH, Goldstein P, et al. STREAM Investigative Team. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2013; 368(15): 1379–1387.
- Gershlick AH, Khan JN, Kelly DJ, et al. Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial. J Am Coll Cardiol. 2015; 65(10): 963–972.
- Wald DS, Morris JK, Wald NJ, et al. PRAMI Investigators. Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med. 2013; 369(12): 1115–1123.
- Engstrøm T, Kelbæk H, Helqvist S, et al. Third Danish Study of Optimal Acute Treatment of Patients With ST Elevation Myocardial Infarction–Ischemic Postconditioning (DANAMI-3–iPOST) Investigators, DANAMI 3 Investigators. The third Danish study of optimal acute treatment of patients with ST-segment elevation myocardial infarction: ischemic postconditioning or deferred stent implantation versus conventional primary angioplasty and complete revascularization versus treatment of culprit lesion only: rationale and design of the DANAMI 3 trial program. Am Heart J. 2015; 169(5): 613–621.
- Smits PC, Abdel-Wahab M, Neumann FJ, et al. Compare-Acute Investigators. Fractional Flow Reserve-Guided Multivessel Angioplasty in Myocardial Infarction. N Engl J Med. 2017; 376(13): 1234–1244.
- Steg PhG, James SK, Atar D, et al. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012; 33(20): 2569–2619.
- Sabaté M, Brugaletta S, Cequier A, et al. Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial. Lancet. 2016; 387(10016): 357–366.
- Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol. 2013; 62(6): 496–504.
- Bønaa KH, Mannsverk J, Wiseth R, et al. NORSTENT Investigators. Drug-eluting or bare-metal stents for coronary artery disease. N Engl J Med. 2016; 375(13): 1242–1252.
- Yusuf S, Mehta SR, Chrolavicius S, et al. OASIS-6 Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006; 295(13): 1519–1530.
- Collet JP, Huber K, Cohen M, et al. ATOLL Investigators. A direct comparison of intravenous enoxaparin with unfractionated heparin in primary percutaneous coronary intervention (from the ATOLL trial). Am J Cardiol. 2013; 112(9): 1367–1372.
- Silvain J, Beygui F, Barthélémy O, et al. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. BMJ. 2012; 344: e553.
- Capodanno D, Gargiulo G, Capranzano P, et al. Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary PCI: An updated meta-analysis of 10,350 patients from five randomized clinical trials. Eur Heart J Acute Cardiovasc Care. 2016; 5(3): 253–262.
- Valgimigli M, Frigoli E, Leonardi S, et al. Bivalirudin or unfractionated heparin in acute coronary syndromes. N Engl J Med. 2015; 373(11): 997–1009.
- Valgimigli M, Ariotti S, Costa F. Duration of dual antiplatelet therapy after drug-eluting stent implantation: will we ever reach a consensus? Eur Heart J. 2015; 36(20): 1219–1222.
- Magnuson EA, Bonaca MP, Bhatt DL, et al. PEGASUS-TIMI 54 Trial Investigators, PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015; 372(19): 1791–1800.
- Yeh RW, Secemsky EA, Kereiakes DJ, et al. DAPT Study Investigators, DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014; 371(23): 2155–2166.
- Grines CL, Marsalese DL, Brodie B, et al. Safety and cost-effectiveness of early discharge after primary angioplasty in low risk patients with acute myocardial infarction. PAMI-II Investigators. Primary Angioplasty in Myocardial Infarction. J Am Coll Cardiol. 1998; 31(5): 967–972.
- Newby LK, Hasselblad V, Armstrong PW, et al. Time-based risk assessment after myocardial infarction. Implications for timing of discharge and applications to medical decision-making. Eur Heart J. 2003; 24(2): 182–189.
- Frycz-Kurek AM, Gierlotka M, Gąsior M, et al. Patients with no significant lesions in coronary arteries and ST-segment elevation myocardial infarction have worse outcome than patients with non-ST-segment elevation myocardial infarction: analysis from PL-ACS Registry. Kardiol Pol. 2010; 68(11): 1211–1217.
- Pasupathy S, Air T, Dreyer RP, et al. Systematic review of patients presenting with suspected myocardial infarction and nonobstructive coronary arteries. Circulation. 2015; 131(10): 861–870.